Open AccessThe prognostic utility of plasma osteopontin in CAP patients
Author(s) -
Ahmed Sh. Mohamed,
Ibrahim S. Ibrahim,
Ragia Samir Sharshar,
Amira Y. Abd El-Naby
Publication year - 2017
Publication title -
egyptian journal of chest diseases and tuberculosis/egyptian journal of chest diseases and tuberculosis
Language(s) - English
Resource type - Journals
eISSN - 2090-9950
pISSN - 0422-7638
DOI - 10.1016/j.ejcdt.2017.10.010
Subject(s) - osteopontin , medicine , biomarker , plasma levels , glycoprotein , gastroenterology , pneumonia , oncology , biology , biochemistry , microbiology and biotechnology
Background: Osteopontin (OPN) is a soluble cytokine glycoprotein widely expressed in many benign and malignant conditions. Purpose of study: was to investigate role of plasma OPN as new biomarker affects prognosis in CAP. Methodology: study was done on 50 subjects divided into 2 groups each 25, CAP (group I), healthy controls (group II). Plasma OPN levels were measured on initial hospitalization and after 3 days of treatment and correlated to severity of CAP by CRP and CURB-65. We concluded that: plasma levels of OPN is increased in pneumonia patients than in healthy controls also before than after 3 days of treatment of CAP. OPN levels significantly correlated with CURB-65 scores but not with CRP levels. Thus, OPN can be used as a novel additional marker, reflecting severity and response to treatment in CAP